Pregnancy-associated plasma protein-A - Revision history

Z8600021 at 13:49, 19 March 2018

2018-03-19T13:49:40Z

← Older revision		Revision as of 00:49, 20 March 2018
Line 19:		Line 19:
	* increased PAPP-A indicate increased risk of trisomy 21		* increased PAPP-A indicate increased risk of trisomy 21
	* reduced PAPP-A associated with an increased risk of trisomy 18		* reduced PAPP-A associated with an increased risk of trisomy 18
	* First trimester low PAPP-A (< 0.4 MoM) associated with an increased frequency of adverse obstetrical outcomes.<ref>Obstetrical complications associated with abnormal maternal serum markers analytes. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. J Obstet Gynaecol Can. 2008 Oct;30(10):918-49. Review. [http://www.ncbi.nlm.nih.gov/pubmed/19038077 PMID: 19038077~~]</ref>~~		* First trimester low PAPP-A (< 0.4 MoM) associated with an increased frequency of adverse obstetrical outcomes.{{#pmid:19038077\|PMID19038077}}

	==Protein==		==Protein==

	* large zinc glycoprotein <ref>Amino acid sequence of human pregnancy-associated plasma protein-A derived from cloned cDNA. Kristensen T, Oxvig C, Sand O, Møller NP, Sottrup-Jensen L. Biochemistry. 1994 Feb 15;33(6):1592-8. [http://www.ncbi.nlm.nih.gov/pubmed/7508748 PMID: 7508748]</ref> <ref>Complete cDNA sequence of the preproform of human pregnancy-associated plasma protein-A. Evidence for expression in the brain and induction by cAMP. Haaning J, Oxvig C, Overgaard MT, Ebbesen P, Kristensen T, Sottrup-Jensen L. Eur J Biochem. 1996 Apr 1;237(1):159-63. [http://www.ncbi.nlm.nih.gov/pubmed/8620868 PMID: 8620868~~]</ref>~~		* large zinc glycoprotein{{#pmid:7508748\|PMID7508748}}{{#pmid:8620868\|PMID8620868}}
	* secreted metalloproteinase (EC=3.4.24.79) which cleaves insulin-like growth factor binding proteins (IGFBPs).		* secreted metalloproteinase (EC=3.4.24.79) which cleaves insulin-like growth factor binding proteins (IGFBPs).
	** specifically cleaves IGFBP-4 and IGFBP-5, releasing bound IGF		** specifically cleaves IGFBP-4 and IGFBP-5, releasing bound IGF
	* present in pregnancy serum		* present in pregnancy serum
	** heterotetrameric 2:2 complex with proform of eosinophil major basic protein (proMBP).<ref>Complex of pregnancy-associated plasma protein-A and the proform of eosinophil major basic protein. Disulfide structure and carbohydrate attachment. Overgaard MT, Sorensen ES, Stachowiak D, Boldt HB, Kristensen L, Sottrup-Jensen L, Oxvig C. J Biol Chem. 2003 Jan 24;278(4):2106-17. Epub 2002 Nov 5. [http://www.ncbi.nlm.nih.gov/pubmed/12421832 PMID: 12421832~~]</ref>~~		** heterotetrameric 2:2 complex with proform of eosinophil major basic protein (proMBP).{{#pmid:12421832\|PMID12421832}}
	** approximate 500 kDa complex called PAPP-A/proMBP.		** approximate 500 kDa complex called PAPP-A/proMBP.
	* placental origin		* placental origin
Line 43:		Line 43:


	{{~~Template:~~Prenatal Diagnosis terms}}		{{Prenatal Diagnosis terms}}
	{{~~Template:~~Glossary}}
	{{~~Template:~~Footer}}		{{Glossary}}

			{{Footer}}

S8600021: /* References */

2010-03-28T12:43:53Z

References

← Older revision		Revision as of 23:43, 28 March 2010
Line 38:		Line 38:
	==References==		==References==
	<references/>		<references/>


			'''Search PubMed:''' [http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=search&term=Pregnancy-associated_plasma_protein-A Pregnancy-associated plasma protein-A]


	{{Template:Prenatal Diagnosis terms}}		{{Template:Prenatal Diagnosis terms}}
	{{Template:Glossary}}		{{Template:Glossary}}
	{{Template:Footer}}		{{Template:Footer}}

S8600021 at 02:46, 28 March 2010

2010-03-28T02:46:26Z

← Older revision		Revision as of 13:46, 28 March 2010
Line 39:		Line 39:
	<references/>		<references/>

			{{Template:Prenatal Diagnosis terms}}
	{{Template:Glossary}}		{{Template:Glossary}}
	{{Template:Footer}}		{{Template:Footer}}

S8600021 at 02:07, 28 March 2010

2010-03-28T02:07:38Z

← Older revision		Revision as of 13:07, 28 March 2010
Line 38:		Line 38:
	==References==		==References==
	<references/>		<references/>

			{{Template:Glossary}}
			{{Template:Footer}}

S8600021 at 02:07, 28 March 2010

2010-03-28T02:07:09Z

← Older revision		Revision as of 13:07, 28 March 2010
Line 34:		Line 34:
	** seminal vesicles and seminal fluid of males		** seminal vesicles and seminal fluid of males

	'''Links:''' [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176385 OMIM] \| [http://www.genecards.org/cgi-bin/carddisp.pl?gene=PAPPA GeneCards] \| [http://www.uniprot.org/uniprot/Q13219~~#section_comments~~ UniProtKB/Swiss-Prot]		'''Links:''' [http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=176385 OMIM] \| [http://www.genecards.org/cgi-bin/carddisp.pl?gene=PAPPA GeneCards] \| [http://www.uniprot.org/uniprot/Q13219 UniProtKB/Swiss-Prot]

	==References==		==References==
	<references/>		<references/>

S8600021: /* PAPP-A Levels */

2010-03-28T02:06:12Z

PAPP-A Levels

← Older revision		Revision as of 13:06, 28 March 2010
Line 13:		Line 13:
	==PAPP-A Levels==		==PAPP-A Levels==
	* Levels of PAPP-A rise from initial detection at about 32 days after ovulation, then increasing rapidly (levels doubling every 3 days), finally continuing to rise more slowly until term.		* Levels of PAPP-A rise from initial detection at about 32 days after ovulation, then increasing rapidly (levels doubling every 3 days), finally continuing to rise more slowly until term.
	* First trimester low PAPP-A (< 0.4 MoM) associated with an increased frequency of adverse obstetrical outcomes.<ref>Obstetrical complications associated with abnormal maternal serum markers analytes. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. J Obstet Gynaecol Can. 2008 Oct;30(10):918-49. Review. [http://www.ncbi.nlm.nih.gov/pubmed/19038077 PMID: 19038077]</ref>
	* Electroimmunoassays allow the detection as early as the fifth week of pregnancy, of circulating levels down to 10 microgram/L.		* Electroimmunoassays allow the detection as early as the fifth week of pregnancy, of circulating levels down to 10 microgram/L.
	* Adult male serum PAPP-A circulating level is 8.03±2.75 mIU/L (mean±SD).		* Adult male serum PAPP-A circulating level is 8.03±2.75 mIU/L (mean±SD).

			Maternal serum level
			* increased PAPP-A indicate increased risk of trisomy 21
			* reduced PAPP-A associated with an increased risk of trisomy 18
			* First trimester low PAPP-A (< 0.4 MoM) associated with an increased frequency of adverse obstetrical outcomes.<ref>Obstetrical complications associated with abnormal maternal serum markers analytes. Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, Désilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynaecologists of Canada Genetics Committee. J Obstet Gynaecol Can. 2008 Oct;30(10):918-49. Review. [http://www.ncbi.nlm.nih.gov/pubmed/19038077 PMID: 19038077]</ref>

	==Protein==		==Protein==

S8600021: /* Introduction */

2010-03-28T01:55:42Z

Introduction

← Older revision		Revision as of 12:55, 28 March 2010
Line 9:		Line 9:
	'''Alternative names:''' pappalysin 1, PAPP-A, PAPPA1, SP4, high molecular weight alpha-2 mobile pregnancy-specific protein, IGFBP4 protease (IGFBP-4ase), ASBABP2, DIPLA1, PAPA		'''Alternative names:''' pappalysin 1, PAPP-A, PAPPA1, SP4, high molecular weight alpha-2 mobile pregnancy-specific protein, IGFBP4 protease (IGFBP-4ase), ASBABP2, DIPLA1, PAPA

	{{Template:Prenatal diagnosis}} \| [http://embryology.med.unsw.edu.au/Defect/PAPP-A.htm Original PAPP-A page~~] \| [[Trisomy 21\|Trisomy 21]~~]		{{Template:Prenatal diagnosis}} \| [[Trisomy 21\|Trisomy 21]] \| [http://embryology.med.unsw.edu.au/Defect/PAPP-A.htm Original PAPP-A page]

	==PAPP-A Levels==		==PAPP-A Levels==

S8600021 at 01:55, 28 March 2010

2010-03-28T01:55:20Z

← Older revision		Revision as of 12:55, 28 March 2010
Line 9:		Line 9:
	'''Alternative names:''' pappalysin 1, PAPP-A, PAPPA1, SP4, high molecular weight alpha-2 mobile pregnancy-specific protein, IGFBP4 protease (IGFBP-4ase), ASBABP2, DIPLA1, PAPA		'''Alternative names:''' pappalysin 1, PAPP-A, PAPPA1, SP4, high molecular weight alpha-2 mobile pregnancy-specific protein, IGFBP4 protease (IGFBP-4ase), ASBABP2, DIPLA1, PAPA

	{{Template:Prenatal diagnosis}} \| [http://embryology.med.unsw.edu.au/Defect/PAPP-A.htm Original PAPP-A page]		{{Template:Prenatal diagnosis}} \| [http://embryology.med.unsw.edu.au/Defect/PAPP-A.htm Original PAPP-A page] \| [[Trisomy 21\|Trisomy 21]]

	==PAPP-A Levels==		==PAPP-A Levels==

S8600021: /* Introduction */

2010-03-28T01:52:49Z

Introduction

← Older revision		Revision as of 12:52, 28 March 2010
Line 1:		Line 1:
	==Introduction==		==Introduction==
	[[File:Prenatal diagnosis- novel serum biomarker screening.png\|thumb\|Prenatal diagnosis- novel serum biomarker screening		[[File:Prenatal diagnosis- novel serum biomarker screening.png\|thumb\|Prenatal diagnosis- novel serum biomarker screening]]
	Pregnancy-associated plasma protein-A (PAPP-A) largest of the pregnancy associated proteins produced by both the embryo and the placenta ([[S#syncytiocytotrophoblast\|syncytiocytotrophoblasts]]) during pregnancy (Placenta Notes). This protein is thought to have several different functions, including preventing recognition of the fetus by the maternal immune system, matrix mineralization and angiogenesis. Levels of PAPP-A rise from first detection in the first trimester until term.		Pregnancy-associated plasma protein-A (PAPP-A) largest of the pregnancy associated proteins produced by both the embryo and the placenta ([[S#syncytiocytotrophoblast\|syncytiocytotrophoblasts]]) during pregnancy (Placenta Notes). This protein is thought to have several different functions, including preventing recognition of the fetus by the maternal immune system, matrix mineralization and angiogenesis. Levels of PAPP-A rise from first detection in the first trimester until term.

S8600021: /* Introduction */

2010-03-28T01:52:39Z

Introduction

← Older revision		Revision as of 12:52, 28 March 2010
Line 1:		Line 1:
	==Introduction==		==Introduction==
			[[File:Prenatal diagnosis- novel serum biomarker screening.png\|thumb\|Prenatal diagnosis- novel serum biomarker screening
	Pregnancy-associated plasma protein-A (PAPP-A) largest of the pregnancy associated proteins produced by both the embryo and the placenta ([[S#syncytiocytotrophoblast\|syncytiocytotrophoblasts]]) during pregnancy (Placenta Notes). This protein is thought to have several different functions, including preventing recognition of the fetus by the maternal immune system, matrix mineralization and angiogenesis. Levels of PAPP-A rise from first detection in the first trimester until term.		Pregnancy-associated plasma protein-A (PAPP-A) largest of the pregnancy associated proteins produced by both the embryo and the placenta ([[S#syncytiocytotrophoblast\|syncytiocytotrophoblasts]]) during pregnancy (Placenta Notes). This protein is thought to have several different functions, including preventing recognition of the fetus by the maternal immune system, matrix mineralization and angiogenesis. Levels of PAPP-A rise from first detection in the first trimester until term.